These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12109802)

  • 1. Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.
    Blackstock AW; Melin SA; Butler JM; Patton S; Pineau B; Albertson D; Howerton R; Levine E
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):25-8. PubMed ID: 12109802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
    Mishra G; Butler J; Ho C; Melin S; Case LD; Ennever PR; Magrinat GC; Bearden JD; Minotto DC; Howerton R; Levine E; Blackstock AW
    Am J Clin Oncol; 2005 Aug; 28(4):345-50. PubMed ID: 16062075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
    Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
    Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
    Bhargava P; Jani CR; Savarese DM; O'Donnell JL; Stuart KE; Rocha Lima CM
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):23-6. PubMed ID: 14569844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
    Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
    Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
    Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
    Lipton A; Harvey H; Witters L; Kerr S; Legore K; Campbell C
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):43-5. PubMed ID: 15685834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
    Stathopoulos GP; Rigatos SK; Dimopoulos MA; Giannakakis T; Foutzilas G; Kouroussis C; Janninis D; Aravantinos G; Androulakis N; Agelaki S; Stathopoulos JG; Georgoulias V;
    Ann Oncol; 2003 Mar; 14(3):388-94. PubMed ID: 12598343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
    Rocha Lima CM; Sherman CA; Brescia FJ; Brunson CY; Green MR
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):46-51. PubMed ID: 11301841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
    Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
    Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
    Rocha Lima CM; Savarese D; Bruckner H; Dudek A; Eckardt J; Hainsworth J; Yunus F; Lester E; Miller W; Saville W; Elfring GL; Locker PK; Compton LD; Miller LL; Green MR
    J Clin Oncol; 2002 Mar; 20(5):1182-91. PubMed ID: 11870159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
    Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
    J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
    Rocha Lima CM; Leong SS; Sherman CA; Perkel JA; Putman T; Safa AR; Green MR
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):19-24. PubMed ID: 12109801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel followed by gemcitabine and irinotecan in solid tumors.
    Rocha Lima CM; Urbanic JJ; Sherman CA; Brescia FJ; Green MR
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):37-45. PubMed ID: 11221020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
    Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
    Stathopoulos GP; Syrigos K; Aravantinos G; Polyzos A; Papakotoulas P; Fountzilas G; Potamianou A; Ziras N; Boukovinas J; Varthalitis J; Androulakis N; Kotsakis A; Samonis G; Georgoulias V
    Br J Cancer; 2006 Sep; 95(5):587-92. PubMed ID: 16909140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.